Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S. Davids(Dana-Farber Cancer Institute), Ian W. Flinn(Tennessee Oncology), Enrico Derenzini(University of Milan), Manish R. Patel(Sarah Cannon), Hari P. Miskin(CDG Therapeutics (United States)), Lori A. Leslie(Hackensack University Medical Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), John N. Allan(Cornell University), John M. Pagel(University of Washington), Danielle M. Brander(Duke University), James Essell(Oncology Hematology Care), Ruth Pettengell(University College Hospital), John M. Burke(Certara (United States)), Tycel Phillips(Michigan Medicine), James A. Reeves(Sarah Cannon), Richy Agajanian(Oncology Institute of Hope and Innovation), Chan Y. Cheah(The University of Western Australia), Timothy S. Fenske(Medical College of Wisconsin), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Peter Sportelli(CDG Therapeutics (United States)), Nilanjan Ghosh(Levine Cancer Institute), Wanda Knopińska‐Posłuszny, Bruce D. Cheson(Center for Cancer and Blood Disorders), Julio C. Chávez(Moffitt Cancer Center), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Wojciech Jurczak(Jagiellonian University), Gustavo Fonseca(Sarah Cannon), Michael Weiss(University of Münster), Yanzhi Hsu(CDG Therapeutics (United States)), Owen A. O’Connor(Virginia Cancer Institute)
Cited by 21
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k